Literature DB >> 172496

Structural requirements for the interaction of 1 alpha, 25-(OH) 2- vitiamin D3 with its chick interestinal receptor system.

D A Procsal, W H Okamura, A W Norman.   

Abstract

The mechanism by which 1 alpha,25-dihydroxycholecalciferol (1alpha,25-(OH)2D3), the biologically active metabolite of cholecalciferol (vitamin D3), stimulates intestinal calcium absorption has been shown to involve an interaction of the steroid with a specific cytosol-chromatin receptor system in this target organ. Thus, 1alpha,12(OH)2D3 binds to a specific cytoplasmic receptor protein and then, following a temperature-dependent step, becomes associated with a finite number of chromatin acceptor sites prior to the initiation of the physiological response. In this respect, 1alpha,25(OH) 2D3 is similar to a number of other steroid hormones. In this investigation, studies were performed to help define the essential structural features required for interaction of 1alpha,25-(OH)2D3 with its intestinal receptor system, and presumably, for biological activity. To this end, competition studies utilizing a series of closely related structural analogs of cholecalciferol were carried out by means of a competitive binding assay highly specific for 1alpha,25(OH)2D3. The competitive binding assay employed in this study is dependent upon the ability to duplicate, in vitro, the conditions which permit the saturable binding of 1alpha,25-(OH)2[3H]D3 to chick intestinal chromatin, in vivo. Optimal conditions for this assay were achieved by the incubation of a reconstituted intestinal receptor system consisting of separately isolated cytosol and Triton X-100 chromatin fractions at 25 degrees for 45 min with 2.0 X 10-8 M 1alpha,25-(OH)2[3H]D3. Maximal binding of about 21 to 24 pmol of radioactive steroid bound per chick intestinal chromatin occurred under these conditions. The ability of the various analogs to compete with the radioactive hormone was assessed by virtue of a decrease in the amount of radioactive steroid bound to the chromatin in the presence of increasing concentrations of nonradioactive analog.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 172496

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.

Authors:  A S Brickman; J W Coburn; G R Friedman; W H Okamura; S G Massry; A W Norman
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

2.  A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications.

Authors:  Mathew T Mizwicki; Danusa Menegaz; Sepideh Yaghmaei; Helen L Henry; Anthony W Norman
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-14       Impact factor: 4.292

3.  Studies on the mode of action of vitamin D XXXVII 1 alpha-hydroxyvitamin D3: a long-acting 1,25-dihydroxyvitamin D3 analog.

Authors:  M R Walters; W Hunziker; J E Bishop; A W Norman
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

4.  Effects of vitamin D metabolites and analogs on bone collagen synthesis in vitro.

Authors:  F R Bringhurst; J T Potts
Journal:  Calcif Tissue Int       Date:  1982-01       Impact factor: 4.333

5.  A monolog on analogs: in vitro effects of vitamin D metabolites and consideration of the mineralization question.

Authors:  P H Stern
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

6.  Effects of vitamin D3, 25-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3 on parathyroid hormone secretion.

Authors:  L K Cantley; J B Russell; D S Lettieri; L M Sherwood
Journal:  Calcif Tissue Int       Date:  1987-07       Impact factor: 4.333

7.  The interaction of 1,25-dihydroxyvitamin D3 with its intestinal mucosa receptor: kinetic parameters and structural requirements.

Authors:  J A Putkey; W R Wecksler; A W Norman
Journal:  Lipids       Date:  1978-10       Impact factor: 1.880

8.  Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.

Authors:  J Pietrek; F Kokot; J Kuska
Journal:  Int Urol Nephrol       Date:  1978       Impact factor: 2.370

9.  Interaction of the 1 alpha,25-dihydroxyvitamin D3 receptor with RNA and synthetic polyribonucleotides.

Authors:  R T Franceschi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

10.  Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients.

Authors:  Nihil Chitalia; Tuan Ismail; Laura Tooth; Frances Boa; Geeta Hampson; David Goldsmith; Juan Carlos Kaski; Debasish Banerjee
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.